Last reviewed · How we verify
NCT05248334
A Prospective Study of Ranibizumab in the Treatment of Postoperative Recurrent Vitreous Haemorrhage of Diabetic Retinopathy
Phase 1 trial testing Ranibizumab Injection in Diabetic Retinopathy in 120 participants. Status unknown.
30 December 2024
Quick facts
| Lead sponsor | Tianjin Medical University Eye Hospital |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 10 April 2022 |
| Primary completion | 30 December 2024 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ranibizumab Injection — full drug profile →
- PPV
Conditions studied
- Diabetic Retinopathy — all drugs for Diabetic Retinopathy →
- Postoperative Recurrent Vitreous Hemorrhage — all drugs for Postoperative Recurrent Vitreous Hemorrhage →
- Pars Plana Vitrectomy — all drugs for Pars Plana Vitrectomy →
- Ranibizumab — all drugs for Ranibizumab →
Sponsor
Tianjin Medical University Eye Hospital
Who can join
Adults 18 to 75, any sex, with Diabetic Retinopathy or Postoperative Recurrent Vitreous Hemorrhage. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diabetic retinopathy (DR) is one of the main complications in diabetes, the proliferative diabetic retinopathy (PDR) is the most important one of the reasons leading to decreased vision, PDR is the stage of clinical intervention. Pars plana vitrectomy (PPV) is an effective treatment for PDR, while vitreous haemorrhage (VH) is a common complication after PPV, with incidence ranging from 11.8% to 75%, and is the main cause of reoperation. Anti-Vascular endothelial growth factor (VEGF) therapy for vitreous hemorrhage can inhibit neovascularization and prevent recurrent vitreous haemorrhage after absorption. Previous studies have found that anti-VEGF is a safe and effective treatment for postoperative recurrent VH. In consideration of the psychological and economic factor of patients, this study intends to observe the effectiveness of single vitreous injection of Ranibizumab in the treatment of postoperative recurrent VH on the basis of previous clinical work. Compare the visual acuity, macular thickness, VH recurrence and patient satisfaction between the Ranibizumab group and the PPV group by randomized grouping.To observe the effective rate and clearance time of recurrent VH after Ranibizumab treatment and whether it can effectively reduce the rate of PPV. To provide clinical guidance for the precise treatment of PDR patients, the treatment of PDR patients has important clinical significance and social and economic significance.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Intravitreal Ranibizumab versus Vitreous Lavage for Postoperative Vitreous Hemorrhage in Proliferative Diabetic Retinopathy: A Randomized Controlled Trial.
Chi J, Zhang X, Nie Z, Pan Y, et al · · 2026 · PMID 41858910 · DOI 10.2147/dddt.s557400
Verify or expand the search:
- PubMed search for NCT05248334
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ranibizumab Injection
Trials testing the same drug.
- NCT04444492 — Combination of Ranibizumab and Targeted Laser Photocoagulation · Phase 3 · recruiting
- NCT03999125 — Anti-VEGF Therapy Versus Dexamethasone Implant for DME · Phase 4 · unknown
- NCT04714242 — OCTA and Polypoidal Choroidal Vasculopathy · completed
- NCT03385382 — Ranibizumab Versus Dexamethasone Implant in Diabetic Macular Edema · completed
- NCT03261635 — Ranibizumab Plus Indomethacin · Phase 4 · completed
Other recruiting trials for Diabetic Retinopathy
Currently open trials in the same condition.
- NCT07255326 — Effect of Omega-3 Fatty Acids on Eye Blood Vessels in Type 1 Diabetes · NA · recruiting
- NCT06782997 — Performance of the Electroretinogram, Performed and Interpreted by an Advanced Practice Nurse, in the Screening for Diab · recruiting
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06713720 — Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy · NA · recruiting
- NCT06892353 — AI-Powered DIY Screening System for Diabetic Retinopathy · NA · recruiting
Other Tianjin Medical University Eye Hospital trials
Trials by the same sponsor.
- NCT07494799 — Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear · not yet recruiting
- NCT07449247 — PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention · Phase 1, PHASE2 · not yet recruiting
- NCT05728476 — Microinvasive Pars Plana Vitrectomy Combined ILM Peeling Versus Anti-VEGF Intravitreal Injection for Treatment-naïve Dia · NA · recruiting
- NCT05990829 — Compare the Efficacy of VItrectomy Combined With DExamethasone Implant Versus With Aflibercept in DME Patients Diagnosed · Phase 4 · unknown
- NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05248334 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tianjin Medical University Eye Hospital
- Last refreshed: 12 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05248334.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing